Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin

AIDS

Volumn 23, Issue 6, 2009, Pages 742-744

  Van Luin, Matthijs ^a,b   Brouwer, Anne Marie ^c   Van Ven, Andre Der ^c   De Lange, Wiel ^a   Van Schaik, Ron H N ^d   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c Department of Internal Medicine ^*  (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; ETHAMBUTOL; ISONIAZID; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; TENOFOVIR;

ADULT; AGGRESSION; AGITATION; CASE REPORT; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MIXED INFECTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; TUBERCULOSIS;

EID: 64549116351     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832914a3     Document Type: Letter

References (12)

1. Pozniak AL, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 2005; 6 (Suppl 2):62-83.
2. Working Group of the office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infectedadults and adolescents, 2008. http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentCL.pdf. [Accessed 3 December 2008]
3. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41:681- 690.
4. Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13:675-685.
5. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
6. De Maat MM, Huitema AD, Mulder JW, Meenhorst PL, Van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HI V-1-infected individuals. Br J Clin Pharmacol 2002; 54:378-385.
7. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
8. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488-1495.
9. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81:557-566.
10. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004; 311:34-43.
11. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004; 32:348-358.
12. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver- Commey J, et al. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 2008; 48:1032-1040.